The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
The Molecular Biology of Endometrial Cancers and the Implications for Pathogenesis, Classification, and Targeted Therapies
Open accessAbstract
Background: Understanding and identifying molecular biology and genetics of endometrial cancer are central to the development of novel therapies. This article reviews the molecular basis for genesis of endometrial cancer with regard to pathogenesis, classification, and implications for targeted therapies. Methods: Genes and cellular pathways that may have an important role in endometrial cancers, both endometrioid and non-endometrioid cancers, are identified. Recently studied drugs and potential future drugs that target some of these genes and pathways are reviewed. Results: The most frequent genetic alteration of endometrioid endometrial cancer is PTEN. PI3CA and K-ras mutations are less common but are often associated with PTEN. Alterations in MLH1 and MSH6 are documented with microsatellite instability. β-catenin has a minor but significant association. Conversely, p53 mutation is more often associated with non-endometrioid cancer; others being inactivation of p16 and/or overexpression of HER-2/neu. Absence of E-cadherin is more often than not present in non-endometrioid cancers and is associated with poor prognosis. Novel agents that target the AKT-PI3K-mTOR pathway and those that inhibit epidermal growth factor receptor (EGFR), vascular endothelial growth factors (VEGF), fibroblast growth factor receptor 2 (FGFR2), and folate receptors are currently being investigated. Conclusions: Novel targeted agents, either alone or in combination with cytotoxic agents, may result in superior treatment for patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,775
Two pathogenetic types of endometrial carcinoma
Bokhman, J. V. (1983) · Gynecologic Oncology · doi:10.1016/0090-8258(83)90111-7 · Cited by 2,494
Altered PTEN Expression as a Diagnostic Marker for the Earliest Endometrial Precancers
Mutter, G. L. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.11.924 · Cited by 829
Molecular and Pathologic Aspects of Endometrial Carcinogenesis
Hecht, J. L., & Mutter, G. L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7173 · Cited by 535
High Frequency of Coexistent Mutations of PIK3CA and PTEN Genes in Endometrial Carcinoma
Oda, K., Stokoe, D., Taketani, Y., & McCormick, F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2620 · Cited by 466
Slomovitz, B. M., Lu, K. H., Johnston, T., Coleman, R. L., Munsell, M., Broaddus, R. R., Walker, C., Ramondetta, L. M., Burke, T. W., Gershenson, D. M., et al. (2010) · Cancer · doi:10.1002/cncr.25515 · Cited by 269
Kurose, K., Zhou, X.-P., Araki, T., Cannistra, S. A., Maher, E. R., & Eng, C. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64681-0 · Cited by 252
Abnormalities of the APC/β-catenin pathway in endometrial cancer
Moreno-Bueno, G., Hardisson, D., Sánchez, C., Sarrió, D., Cassia, R., García-Rostán, G., Prat, J., Guo, M., Herman, J. G., Matías-Guiu, X., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205924 · Cited by 237
Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias.
Maxwell, G. L., Risinger, J. I., Gumbs, C. E., Shaw, H., Bentley, R. C., Barrett, J. C., Berchuck, A., & Futreal, P. A. (1998) · PubMed · Cited by 231
Novel molecular profiles of endometrial cancer—new light through old windows
Doll, A., Abal, M., Rigau, M., Monge, M., Gonzalez, M., Demajo, S., Colás, E., Llauradó, M., Alazzouzi, H., Planagumá, J., et al. (2008) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2007.09.020 · Cited by 212
Cited by
The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer
Slomovitz, B. M., & Coleman, R. L. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0662 · Cited by 397
Potential contribution of the uterine microbiome in the development of endometrial cancer
Walther-António, M. R. S., Chen, J., Multinu, F., Hokenstad, A., Distad, T. J., Cheek, E. H., Keeney, G. L., Creedon, D. J., Nelson, H., Mariani, A., et al. (2016) · Genome Medicine · doi:10.1186/s13073-016-0368-y · Cited by 386
Myatt, S. S., Wang, J., Monteiro, L. J., Christian, M., Ho, K.-K., Fusi, L., Dina, R. E., Brosens, J. J., Ghaem-Maghami, S., & Lam, E. W.-F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1891 · Cited by 318
Amant, F., Mirza, M. R., & Creutzberg, C. L. (2012) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(12)60024-1 · Cited by 309
Cincin, Z. B., Kiran, B., Baran, Y., & Cakmakoglu, B. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.020 · Cited by 56
Metadata
- Authors
- Bansal, N., Yendluri, V., & Wenham, R. M.
- Venue
- Cancer Control
- Publisher
- SAGE Publications
- Published
- 2009-01
- Volume
- 16
- Issue
- 1
- Pages
- 8-13
- ISSN
- 1073-2748 (ISSN-L)
- OpenAlex
- W2132510467
- Cited by
- 311
- References
- 22
- FWCI
- 32.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Molecular Biology of Endometrial Cancers and the Implications for Pathogenesis, Classification, and Targeted Therapies. https://app.cochat.ai/papers/10.1177/107327480901600102
- The paper
- Bansal, N., Yendluri, V., & Wenham, R. M. (2009). The Molecular Biology of Endometrial Cancers and the Implications for Pathogenesis, Classification, and Targeted Therapies. Cancer Control. https://doi.org/10.1177/107327480901600102
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.